FDA scientists consider possible toxicity and birth defects before public meeting next week
US federal health regulators say an experimental Covid-19 pill from Merck is effective but will seek input from outside experts on risks of birth defects and other problems during pregnancy.
The Food and Drug Administration (FDA) posted its analysis of the pill before a public meeting next week where academic and other experts will weigh in. The agency isn’t required to follow the group’s advice.
